International Journal of Hematology and Oncology 2019, Vol 29, Num 4 Page(s): 161-167
ANTIPHOSPHOLIPID ANTIBODY SYNDROME

YAVUZ BEYAZIT1, MURAT KEKİLLİ1, SALİH AKSU1, İBRAHİM C. HAZNEDAROĞLU1

Hacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları AD, ANKARA

Keywords: antiphospholipid antibody syndrome, antiphospholipid antibodies, clinical features, management
The antiphospholipid syndrome(APL) is an autoimmune disorder characterized by arterial or venous thrombosis, recurrent abortus, and thrombocytopenia combined with laboratory tests that indicate the presence of antibodies against phospholipid-binding proteins. The term "antiphospholipid syndrome" was first coined to denote the clinical association between antiphospholipid antibodies and a syndrome of hypercoagulability. Clinically relevant APL antibodies are mainly anticardiolipin antibodies (ACA) detected by solid phase enzyme-linked immunosorbent assay (ELISA) and lupus anticoagulants (LA) demonstrated by in vitro coagulation assay. However, there are some other antibodies associated with the APL syndrome (i.e. subgroup APL antibodies). Several treatments with the use of following medications have been proposed such as low dose aspirin, low or immunosuppressive doses of corticosteroids, and preventive or therapeutic doses of heparin and intravenous immunoglobulin.